Phase-I study of vismodegib in children with recurrent or refractory medulloblastoma: a Pediatric Brain Tumor Consortium (PBTC) study

PURPOSE: To investigate the safety, dose-limiting toxicities, and pharmacokinetics of the smoothened inhibitor vismodegib in children with refractory or relapsed medulloblastoma. PATIENTS AND METHODS: Initially, vismodegib was administered daily at 85 mg/m(2) and escalated to 170 mg/m(2). The study...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gajjar, Amar, Stewart, Clinton F., Ellison, David W., Kaste, Sue, Kun, Larry E., Packer, Roger J., Goldman, Stewart, Chintagumpala, Murali, Wallace, Dana, Takebe, Naoko, Boyett, James M., Gilbertson, Richard J., Curran, Tom
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3856244/
https://ncbi.nlm.nih.gov/pubmed/24077351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1425
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados